ID   KS6A3_HUMAN             Reviewed;         740 AA.
AC   P51812; B2R9V4; Q4VAP3; Q59H26; Q5JPK8; Q7Z3Z7;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   10-MAY-2017, entry version 182.
DE   RecName: Full=Ribosomal protein S6 kinase alpha-3;
DE            Short=S6K-alpha-3;
DE            EC=2.7.11.1;
DE   AltName: Full=90 kDa ribosomal protein S6 kinase 3;
DE            Short=p90-RSK 3;
DE            Short=p90RSK3;
DE   AltName: Full=Insulin-stimulated protein kinase 1;
DE            Short=ISPK-1;
DE   AltName: Full=MAP kinase-activated protein kinase 1b;
DE            Short=MAPK-activated protein kinase 1b;
DE            Short=MAPKAP kinase 1b;
DE            Short=MAPKAPK-1b;
DE   AltName: Full=Ribosomal S6 kinase 2;
DE            Short=RSK-2;
DE   AltName: Full=pp90RSK2;
GN   Name=RPS6KA3; Synonyms=ISPK1, MAPKAPK1B, RSK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta, and T-cell;
RX   PubMed=7813820; DOI=10.2337/diab.44.1.90;
RA   Bjoerbaek C., Vik T.A., Echwald S.M., Webb G.C., Wang J.P.,
RA   Yang P.-Y., Vestergaard H., Richmond K., Hansen T., Erikson R.L.,
RA   Miklos G.L.G., Cohen P.T.W., Pedersen O.;
RT   "Cloning of a human insulin-stimulated protein kinase (ISPK-1) gene
RT   and analysis of coding regions and mRNA levels of the ISPK-1 and the
RT   protein phosphatase-1 genes in muscle from NIDDM patients.";
RL   Diabetes 44:90-97(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2-582.
RC   TISSUE=Skeletal muscle;
RX   PubMed=8141249;
RA   Moller D.E., Xia C.-H., Tang W., Zhu A.X., Jakubowski M.;
RT   "Human rsk isoforms: cloning and characterization of tissue-specific
RT   expression.";
RL   Am. J. Physiol. 266:C351-C359(1994).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 15-735.
RX   PubMed=12777533; DOI=10.1093/molbev/msg134;
RA   Kitano T., Schwarz C., Nickel B., Paeaebo S.;
RT   "Gene diversity patterns at 10 X-chromosomal loci in humans and
RT   chimpanzees.";
RL   Mol. Biol. Evol. 20:1281-1289(2003).
RN   [8]
RP   FUNCTION IN PHOSPHORYLATION OF GSK3B.
RX   PubMed=8250835; DOI=10.1042/bj2960015;
RA   Sutherland C., Leighton I.A., Cohen P.;
RT   "Inactivation of glycogen synthase kinase-3 beta by phosphorylation:
RT   new kinase connections in insulin and growth-factor signalling.";
RL   Biochem. J. 296:15-19(1993).
RN   [9]
RP   FUNCTION IN PHOSPHORYLATION OF CREB1.
RX   PubMed=9770464; DOI=10.1073/pnas.95.21.12202;
RA   De Cesare D., Jacquot S., Hanauer A., Sassone-Corsi P.;
RT   "Rsk-2 activity is necessary for epidermal growth factor-induced
RT   phosphorylation of CREB protein and transcription of c-fos gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:12202-12207(1998).
RN   [10]
RP   FUNCTION IN PHOSPHORYLATION OF HISTONE H3.
RX   PubMed=10436156; DOI=10.1126/science.285.5429.886;
RA   Sassone-Corsi P., Mizzen C.A., Cheung P., Crosio C., Monaco L.,
RA   Jacquot S., Hanauer A., Allis C.D.;
RT   "Requirement of Rsk-2 for epidermal growth factor-activated
RT   phosphorylation of histone H3.";
RL   Science 285:886-891(1999).
RN   [11]
RP   FUNCTION IN PHOSPHORYLATION OF DAPK1.
RX   PubMed=16213824; DOI=10.1016/j.cub.2005.08.050;
RA   Anjum R., Roux P.P., Ballif B.A., Gygi S.P., Blenis J.;
RT   "The tumor suppressor DAP kinase is a target of RSK-mediated survival
RT   signaling.";
RL   Curr. Biol. 15:1762-1767(2005).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF NR4A1/NUR77.
RX   PubMed=16223362; DOI=10.1042/BJ20050967;
RA   Wingate A.D., Campbell D.G., Peggie M., Arthur J.S.;
RT   "Nur77 is phosphorylated in cells by RSK in response to mitogenic
RT   stimulation.";
RL   Biochem. J. 393:715-724(2006).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-715, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [14]
RP   INTERACTION WITH NFATC4.
RX   PubMed=17213202; DOI=10.1074/jbc.M611322200;
RA   Cho Y.-Y., Yao K., Bode A.M., Bergen H.R. III, Madden B.J., Oh S.-M.,
RA   Ermakova S., Kang B.S., Choi H.S., Shim J.-H., Dong Z.;
RT   "RSK2 mediates muscle cell differentiation through regulation of
RT   NFAT3.";
RL   J. Biol. Chem. 282:8380-8392(2007).
RN   [15]
RP   FUNCTION IN PHOSPHORYLATION OF RPS6.
RX   PubMed=17360704; DOI=10.1074/jbc.M700906200;
RA   Roux P.P., Shahbazian D., Vu H., Holz M.K., Cohen M.S., Taunton J.,
RA   Sonenberg N., Blenis J.;
RT   "RAS/ERK signaling promotes site-specific ribosomal protein S6
RT   phosphorylation via RSK and stimulates cap-dependent translation.";
RL   J. Biol. Chem. 282:14056-14064(2007).
RN   [16]
RP   FUNCTION IN MTOR SIGNALING.
RX   PubMed=18722121; DOI=10.1016/j.cub.2008.07.078;
RA   Carriere A., Cargnello M., Julien L.A., Gao H., Bonneil E.,
RA   Thibault P., Roux P.P.;
RT   "Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-
RT   mediated raptor phosphorylation.";
RL   Curr. Biol. 18:1269-1277(2008).
RN   [17]
RP   REVIEW ON FUNCTION, AND REVIEW ON ENZYME REGULATION.
RX   PubMed=18508509; DOI=10.2741/3003;
RA   Carriere A., Ray H., Blenis J., Roux P.P.;
RT   "The RSK factors of activating the Ras/MAPK signaling cascade.";
RL   Front. Biosci. 13:4258-4275(2008).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-365; SER-369; SER-375;
RP   SER-386; SER-415; SER-556 AND SER-715, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [19]
RP   REVIEW ON FUNCTION, AND REVIEW ON ENZYME REGULATION.
RX   PubMed=18813292; DOI=10.1038/nrm2509;
RA   Anjum R., Blenis J.;
RT   "The RSK family of kinases: emerging roles in cellular signalling.";
RL   Nat. Rev. Mol. Cell Biol. 9:747-758(2008).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-365; SER-369 AND
RP   SER-375, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-365; SER-369; SER-375;
RP   SER-386; SER-415 AND SER-715, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-415, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-715, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-365 AND SER-369, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-365; SER-369; SER-415
RP   AND SER-715, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-369; SER-386; SER-415
RP   AND SER-715, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [28]
RP   FUNCTION IN PHOSPHORYLATION OF EPHA2.
RX   PubMed=26158630; DOI=10.1038/ncomms8679;
RA   Zhou Y., Yamada N., Tanaka T., Hori T., Yokoyama S., Hayakawa Y.,
RA   Yano S., Fukuoka J., Koizumi K., Saiki I., Sakurai H.;
RT   "Crucial roles of RSK in cell motility by catalysing serine
RT   phosphorylation of EphA2.";
RL   Nat. Commun. 6:7679-7679(2015).
RN   [29]
RP   VARIANTS CLS VAL-75 AND ALA-227.
RX   PubMed=8955270; DOI=10.1038/384567a0;
RA   Trivier E., de Cesare D., Jacquot S., Pannetier S., Zackai E.,
RA   Young I., Mandel J.-L., Sassone-Corsi P., Hanauer A.;
RT   "Mutations in the kinase Rsk-2 associated with Coffin-Lowry
RT   syndrome.";
RL   Nature 384:567-570(1996).
RN   [30]
RP   VARIANTS CLS PHE-82; GLN-127; TYR-154; VAL-225 AND ASP-431, AND
RP   VARIANT SER-38.
RX   PubMed=9837815; DOI=10.1086/302153;
RA   Jacquot S., Merienne K., de Cesare D., Pannetier S., Mandel J.-L.,
RA   Sassone-Corsi P., Hanauer A.;
RT   "Mutation analysis of the RSK2 gene in Coffin-Lowry patients:
RT   extensive allelic heterogeneity and a high rate of De novo
RT   mutations.";
RL   Am. J. Hum. Genet. 63:1631-1640(1998).
RN   [31]
RP   VARIANTS CLS TRP-114 AND GLN-729.
RX   PubMed=10094187; DOI=10.1038/sj.ejhg.5200231;
RA   Abidi F., Jacquot S., Lassiter C., Trivier E., Hanauer A.,
RA   Schwartz C.E.;
RT   "Novel mutations in Rsk-2, the gene for Coffin-Lowry syndrome (CLS).";
RL   Eur. J. Hum. Genet. 7:20-26(1999).
RN   [32]
RP   VARIANT CLS LYS-189.
RX   PubMed=10528858; DOI=10.1136/jmg.36.10.775;
RA   Manouvrier-Hanu S., Amiel J., Jacquot S., Merienne K., Moerman A.,
RA   Coeslier A., Labarriere F., Vallee L., Croquette M.F., Hanauer A.;
RT   "Unreported RSK2 missense mutation in two male sibs with an unusually
RT   mild form of Coffin-Lowry syndrome.";
RL   J. Med. Genet. 36:775-778(1999).
RN   [33]
RP   VARIANT MRX19 TRP-383, AND CHARACTERIZATION OF VARIANT MRX19 TRP-383.
RX   PubMed=10319851; DOI=10.1038/8719;
RA   Merienne K., Jacquot S., Pannetier S., Zeniou M., Bankier A., Gecz J.,
RA   Mandel J.L., Mulley J., Sassone-Corsi P., Hanauer A.;
RT   "A missense mutation in RPS6KA3 (RSK2) responsible for non-specific
RT   mental retardation.";
RL   Nat. Genet. 22:13-14(1999).
RN   [34]
RP   VARIANT CLS SER-268.
RX   PubMed=14986828; DOI=10.1046/j.1399-0004.2003.00166.x;
RA   Martinez-Garay I., Ballesta M.J., Oltra S., Orellana C., Palomeque A.,
RA   Molto M.D., Prieto F., Martinez F.;
RT   "Intronic L1 insertion and F268S, novel mutations in RPS6KA3 (RSK2)
RT   causing Coffin-Lowry syndrome.";
RL   Clin. Genet. 64:491-496(2003).
RN   [35]
RP   VARIANT CLS ILE-477 DEL.
RX   PubMed=15214012; DOI=10.1002/ajmg.a.30056;
RA   Facher J.J., Regier E.J., Jacobs G.H., Siwik E., Delaunoy J.P.,
RA   Robin N.H.;
RT   "Cardiomyopathy in Coffin-Lowry syndrome.";
RL   Am. J. Med. Genet. A 128:176-178(2004).
RN   [36]
RP   VARIANTS MRX19 SER-115; GLY-152 DEL AND ASP-202 DEL.
RX   PubMed=17100996; DOI=10.1111/j.1399-0004.2006.00723.x;
RA   Field M., Tarpey P., Boyle J., Edkins S., Goodship J., Luo Y.,
RA   Moon J., Teague J., Stratton M.R., Futreal P.A., Wooster R.,
RA   Raymond F.L., Turner G.;
RT   "Mutations in the RSK2(RPS6KA3) gene cause Coffin-Lowry syndrome and
RT   nonsyndromic X-linked mental retardation.";
RL   Clin. Genet. 70:509-515(2006).
RN   [37]
RP   VARIANT [LARGE SCALE ANALYSIS] VAL-416.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [38]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-38; CYS-483; PHE-608 AND CYS-723.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase that acts downstream of
CC       ERK (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic
CC       and stress-induced activation of the transcription factors CREB1,
CC       ETV1/ER81 and NR4A1/NUR77, regulates translation through RPS6 and
CC       EIF4B phosphorylation, and mediates cellular proliferation,
CC       survival, and differentiation by modulating mTOR signaling and
CC       repressing pro-apoptotic function of BAD and DAPK1. In fibroblast,
CC       is required for EGF-stimulated phosphorylation of CREB1 and
CC       histone H3 at 'Ser-10', which results in the subsequent
CC       transcriptional activation of several immediate-early genes. In
CC       response to mitogenic stimulation (EGF and PMA), phosphorylates
CC       and activates NR4A1/NUR77 and ETV1/ER81 transcription factors and
CC       the cofactor CREBBP. Upon insulin-derived signal, acts indirectly
CC       on the transcription regulation of several genes by
CC       phosphorylating GSK3B at 'Ser-9' and inhibiting its activity.
CC       Phosphorylates RPS6 in response to serum or EGF via an mTOR-
CC       independent mechanism and promotes translation initiation by
CC       facilitating assembly of the preinitiation complex. In response to
CC       insulin, phosphorylates EIF4B, enhancing EIF4B affinity for the
CC       EIF3 complex and stimulating cap-dependent translation. Is
CC       involved in the mTOR nutrient-sensing pathway by directly
CC       phosphorylating TSC2 at 'Ser-1798', which potently inhibits TSC2
CC       ability to suppress mTOR signaling, and mediates phosphorylation
CC       of RPTOR, which regulates mTORC1 activity and may promote
CC       rapamycin-sensitive signaling independently of the PI3K/AKT
CC       pathway. Mediates cell survival by phosphorylating the pro-
CC       apoptotic proteins BAD and DAPK1 and suppressing their pro-
CC       apoptotic function. Promotes the survival of hepatic stellate
CC       cells by phosphorylating CEBPB in response to the hepatotoxin
CC       carbon tetrachloride (CCl4). Is involved in cell cycle regulation
CC       by phosphorylating the CDK inhibitor CDKN1B, which promotes CDKN1B
CC       association with 14-3-3 proteins and prevents its translocation to
CC       the nucleus and inhibition of G1 progression. In LPS-stimulated
CC       dendritic cells, is involved in TLR4-induced macropinocytosis, and
CC       in myeloma cells, acts as effector of FGFR3-mediated
CC       transformation signaling, after direct phosphorylation at Tyr-529
CC       by FGFR3. Negatively regulates EGF-induced MAPK1/3 phosphorylation
CC       via phosphorylation of SOS1. Phosphorylates SOS1 at 'Ser-1134' and
CC       'Ser-1161' that create YWHAB and YWHAE binding sites and which
CC       contribute to the negative regulation of MAPK1/3 phosphorylation
CC       (By similarity). Phosphorylates EPHA2 at 'Ser-897', the RPS6KA-
CC       EPHA2 signaling pathway controls cell migration (PubMed:26158630).
CC       {ECO:0000250|UniProtKB:P18654, ECO:0000269|PubMed:10436156,
CC       ECO:0000269|PubMed:16213824, ECO:0000269|PubMed:16223362,
CC       ECO:0000269|PubMed:17360704, ECO:0000269|PubMed:18722121,
CC       ECO:0000269|PubMed:26158630, ECO:0000269|PubMed:8250835,
CC       ECO:0000269|PubMed:9770464}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- ENZYME REGULATION: Upon extracellular signal or mitogen
CC       stimulation, phosphorylated at Thr-577 in the C-terminal kinase
CC       domain (CTKD) by MAPK1/ERK2 and MAPK3/ERK1. The activated CTKD
CC       then autophosphorylates Ser-386, allowing binding of PDPK1, which
CC       in turn phosphorylates Ser-227 in the N-terminal kinase domain
CC       (NTDK) leading to the full activation of the protein and
CC       subsequent phosphorylation of the substrates by the NTKD.
CC   -!- SUBUNIT: Forms a complex with either MAPK1/ERK2 or MAPK3/ERK1 in
CC       quiescent cells. Transiently dissociates following mitogenic
CC       stimulation (By similarity). Interacts with NFATC4, ETV1/ER81 and
CC       FGFR1. {ECO:0000250, ECO:0000269|PubMed:17213202}.
CC   -!- INTERACTION:
CC       P28482:MAPK1; NbExp=3; IntAct=EBI-1046616, EBI-959949;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250}. Cytoplasm
CC       {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Expressed in many tissues, highest levels in
CC       skeletal muscle.
CC   -!- PTM: Activated by phosphorylation at Ser-227 by PDPK1.
CC       Autophosphorylated on Ser-386, as part of the activation process.
CC       May be phosphorylated at Thr-365 and Ser-369 by MAPK1/ERK2 and
CC       MAPK3/ERK1. Can also be activated via phosphorylation at Ser-386
CC       by MAPKAPK2.
CC   -!- PTM: N-terminal myristoylation results in an activated kinase in
CC       the absence of added growth factors.
CC   -!- DISEASE: Coffin-Lowry syndrome (CLS) [MIM:303600]: A X-linked
CC       mental retardation associated with facial and digital
CC       dysmorphisms, progressive skeletal malformations, growth
CC       retardation, hearing deficit and paroxysmal movement disorders.
CC       {ECO:0000269|PubMed:10094187, ECO:0000269|PubMed:10528858,
CC       ECO:0000269|PubMed:14986828, ECO:0000269|PubMed:15214012,
CC       ECO:0000269|PubMed:8955270, ECO:0000269|PubMed:9837815}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Mental retardation, X-linked 19 (MRX19) [MIM:300844]: A
CC       non-syndromic form of mild to moderate mental retardation. Mental
CC       retardation is characterized by significantly below average
CC       general intellectual functioning associated with impairments in
CC       adaptive behavior and manifested during the developmental period.
CC       In contrast to syndromic or specific X-linked mental retardation
CC       which also present with associated physical, neurological and/or
CC       psychiatric manifestations, intellectual deficiency is the only
CC       primary symptom of non-syndromic X-linked mental retardation.
CC       {ECO:0000269|PubMed:10319851, ECO:0000269|PubMed:17100996}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. S6 kinase subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD92170.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U08316; AAA81952.1; -; mRNA.
DR   EMBL; AK313932; BAG36651.1; -; mRNA.
DR   EMBL; AB208933; BAD92170.1; ALT_INIT; mRNA.
DR   EMBL; AL732366; CAI40548.1; -; Genomic_DNA.
DR   EMBL; AL807772; CAI40548.1; JOINED; Genomic_DNA.
DR   EMBL; AL807772; CAI39687.1; -; Genomic_DNA.
DR   EMBL; AL732366; CAI39687.1; JOINED; Genomic_DNA.
DR   EMBL; BC096301; AAH96301.1; -; mRNA.
DR   EMBL; BC096302; AAH96302.1; -; mRNA.
DR   EMBL; BC096303; AAH96303.1; -; mRNA.
DR   EMBL; L07599; AAC82495.1; -; mRNA.
DR   EMBL; AB102662; BAC81131.1; -; mRNA.
DR   CCDS; CCDS14197.1; -.
DR   PIR; I38556; I38556.
DR   RefSeq; NP_004577.1; NM_004586.2.
DR   UniGene; Hs.445387; -.
DR   PDB; 4D9T; X-ray; 2.40 A; A=399-740.
DR   PDB; 4D9U; X-ray; 2.40 A; A=399-740.
DR   PDB; 4JG6; X-ray; 2.60 A; A=399-740.
DR   PDB; 4JG7; X-ray; 3.00 A; A=399-740.
DR   PDB; 4JG8; X-ray; 3.10 A; A=399-740.
DR   PDB; 4NUS; X-ray; 2.39 A; A=39-359.
DR   PDB; 4NW5; X-ray; 1.94 A; A=39-359.
DR   PDB; 4NW6; X-ray; 1.74 A; A=39-359.
DR   PDB; 5D9K; X-ray; 2.55 A; A/B=39-366.
DR   PDB; 5D9L; X-ray; 2.15 A; A=39-359.
DR   PDBsum; 4D9T; -.
DR   PDBsum; 4D9U; -.
DR   PDBsum; 4JG6; -.
DR   PDBsum; 4JG7; -.
DR   PDBsum; 4JG8; -.
DR   PDBsum; 4NUS; -.
DR   PDBsum; 4NW5; -.
DR   PDBsum; 4NW6; -.
DR   PDBsum; 5D9K; -.
DR   PDBsum; 5D9L; -.
DR   ProteinModelPortal; P51812; -.
DR   SMR; P51812; -.
DR   BioGrid; 112111; 55.
DR   DIP; DIP-38247N; -.
DR   IntAct; P51812; 18.
DR   MINT; MINT-1542962; -.
DR   STRING; 9606.ENSP00000368884; -.
DR   BindingDB; P51812; -.
DR   ChEMBL; CHEMBL2345; -.
DR   DrugBank; DB00945; Acetylsalicylic acid.
DR   GuidetoPHARMACOLOGY; 1528; -.
DR   iPTMnet; P51812; -.
DR   PhosphoSitePlus; P51812; -.
DR   BioMuta; RPS6KA3; -.
DR   DMDM; 1730070; -.
DR   EPD; P51812; -.
DR   MaxQB; P51812; -.
DR   PaxDb; P51812; -.
DR   PeptideAtlas; P51812; -.
DR   PRIDE; P51812; -.
DR   DNASU; 6197; -.
DR   Ensembl; ENST00000379565; ENSP00000368884; ENSG00000177189.
DR   GeneID; 6197; -.
DR   KEGG; hsa:6197; -.
DR   UCSC; uc004czu.4; human.
DR   CTD; 6197; -.
DR   DisGeNET; 6197; -.
DR   GeneCards; RPS6KA3; -.
DR   GeneReviews; RPS6KA3; -.
DR   HGNC; HGNC:10432; RPS6KA3.
DR   HPA; CAB003853; -.
DR   HPA; CAB013520; -.
DR   HPA; HPA003221; -.
DR   MalaCards; RPS6KA3; -.
DR   MIM; 300075; gene.
DR   MIM; 300844; phenotype.
DR   MIM; 303600; phenotype.
DR   neXtProt; NX_P51812; -.
DR   OpenTargets; ENSG00000177189; -.
DR   Orphanet; 192; Coffin-Lowry syndrome.
DR   Orphanet; 777; X-linked non-syndromic intellectual disability.
DR   PharmGKB; PA34847; -.
DR   eggNOG; KOG0598; Eukaryota.
DR   eggNOG; ENOG410XNPH; LUCA.
DR   GeneTree; ENSGT00860000133668; -.
DR   HOGENOM; HOG000233033; -.
DR   HOVERGEN; HBG108317; -.
DR   InParanoid; P51812; -.
DR   KO; K04373; -.
DR   OMA; YTLNRQD; -.
DR   OrthoDB; EOG091G05Z7; -.
DR   PhylomeDB; P51812; -.
DR   TreeFam; TF313438; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   Reactome; R-HSA-198753; ERK/MAPK targets.
DR   Reactome; R-HSA-199920; CREB phosphorylation.
DR   Reactome; R-HSA-2559582; Senescence-Associated Secretory Phenotype (SASP).
DR   Reactome; R-HSA-437239; Recycling pathway of L1.
DR   Reactome; R-HSA-442742; CREB phosphorylation through the activation of Ras.
DR   Reactome; R-HSA-444257; RSK activation.
DR   Reactome; R-HSA-881907; Gastrin-CREB signalling pathway via PKC and MAPK.
DR   SignaLink; P51812; -.
DR   SIGNOR; P51812; -.
DR   ChiTaRS; RPS6KA3; human.
DR   GeneWiki; RPS6KA3; -.
DR   GenomeRNAi; 6197; -.
DR   PRO; PR:P51812; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000177189; -.
DR   CleanEx; HS_RPS6KA3; -.
DR   ExpressionAtlas; P51812; baseline and differential.
DR   Genevisible; P51812; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0043027; F:cysteine-type endopeptidase inhibitor activity involved in apoptotic process; IDA:UniProtKB.
DR   GO; GO:0016301; F:kinase activity; TAS:Reactome.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:InterPro.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0019901; F:protein kinase binding; IEA:Ensembl.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0007417; P:central nervous system development; TAS:ProtInc.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; TAS:UniProtKB.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IDA:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; TAS:ARUK-UCL.
DR   GO; GO:0045597; P:positive regulation of cell differentiation; TAS:UniProtKB.
DR   GO; GO:0030307; P:positive regulation of cell growth; TAS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:0043620; P:regulation of DNA-templated transcription in response to stress; TAS:UniProtKB.
DR   GO; GO:0043555; P:regulation of translation in response to stress; TAS:UniProtKB.
DR   GO; GO:0032496; P:response to lipopolysaccharide; ISS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0001501; P:skeletal system development; TAS:ProtInc.
DR   GO; GO:0002224; P:toll-like receptor signaling pathway; ISS:UniProtKB.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR016239; Ribosomal_S6_kinase_II.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 2.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   PIRSF; PIRSF000606; Ribsml_S6_kin_2; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 2.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 2.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 2.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 2.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell cycle; Complete proteome; Cytoplasm;
KW   Disease mutation; Kinase; Magnesium; Mental retardation;
KW   Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; Stress response; Transferase.
FT   CHAIN         1    740       Ribosomal protein S6 kinase alpha-3.
FT                                /FTId=PRO_0000086203.
FT   DOMAIN       68    327       Protein kinase 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      328    397       AGC-kinase C-terminal.
FT   DOMAIN      422    679       Protein kinase 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      74     82       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     428    436       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    193    193       Proton acceptor. {ECO:0000250}.
FT   ACT_SITE    539    539       Proton acceptor. {ECO:0000250}.
FT   BINDING     100    100       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING     451    451       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     227    227       Phosphoserine; by PDPK1. {ECO:0000305}.
FT   MOD_RES     365    365       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     369    369       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     375    375       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   MOD_RES     386    386       Phosphoserine; by autocatalysis and
FT                                MAPKAPK2. {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     415    415       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     529    529       Phosphotyrosine; by FGFR3. {ECO:0000250}.
FT   MOD_RES     556    556       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     715    715       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   VARIANT      38     38       I -> S (in dbSNP:rs56218010).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:9837815}.
FT                                /FTId=VAR_006188.
FT   VARIANT      75     75       G -> V (in CLS; dbSNP:rs122454124).
FT                                {ECO:0000269|PubMed:8955270}.
FT                                /FTId=VAR_006189.
FT   VARIANT      82     82       V -> F (in CLS; dbSNP:rs122454126).
FT                                {ECO:0000269|PubMed:9837815}.
FT                                /FTId=VAR_006190.
FT   VARIANT     114    114       R -> W (in CLS; dbSNP:rs122454127).
FT                                {ECO:0000269|PubMed:10094187}.
FT                                /FTId=VAR_006191.
FT   VARIANT     115    115       T -> S (in MRX19; dbSNP:rs387906703).
FT                                {ECO:0000269|PubMed:17100996}.
FT                                /FTId=VAR_065892.
FT   VARIANT     127    127       H -> Q (in CLS).
FT                                {ECO:0000269|PubMed:9837815}.
FT                                /FTId=VAR_006192.
FT   VARIANT     152    152       Missing (in MRX19).
FT                                {ECO:0000269|PubMed:17100996}.
FT                                /FTId=VAR_065893.
FT   VARIANT     154    154       D -> Y (in CLS).
FT                                {ECO:0000269|PubMed:9837815}.
FT                                /FTId=VAR_006193.
FT   VARIANT     189    189       I -> K (in CLS; dbSNP:rs122454130).
FT                                {ECO:0000269|PubMed:10528858}.
FT                                /FTId=VAR_065894.
FT   VARIANT     202    202       Missing (in MRX19).
FT                                {ECO:0000269|PubMed:17100996}.
FT                                /FTId=VAR_065895.
FT   VARIANT     225    225       A -> V (in CLS).
FT                                {ECO:0000269|PubMed:9837815}.
FT                                /FTId=VAR_006194.
FT   VARIANT     227    227       S -> A (in CLS; dbSNP:rs122454125).
FT                                {ECO:0000269|PubMed:8955270}.
FT                                /FTId=VAR_006195.
FT   VARIANT     268    268       F -> S (in CLS; dbSNP:rs122454131).
FT                                {ECO:0000269|PubMed:14986828}.
FT                                /FTId=VAR_065896.
FT   VARIANT     383    383       R -> W (in MRX19; kinase activity is
FT                                decreased but not abolished;
FT                                dbSNP:rs122454129).
FT                                {ECO:0000269|PubMed:10319851}.
FT                                /FTId=VAR_065897.
FT   VARIANT     416    416       I -> V (in a breast cancer sample;
FT                                somatic mutation; dbSNP:rs148050184).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035627.
FT   VARIANT     431    431       G -> D (in CLS).
FT                                {ECO:0000269|PubMed:9837815}.
FT                                /FTId=VAR_006196.
FT   VARIANT     477    477       Missing (in CLS).
FT                                {ECO:0000269|PubMed:15214012}.
FT                                /FTId=VAR_065898.
FT   VARIANT     483    483       Y -> C (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040629.
FT   VARIANT     608    608       L -> F (in a glioblastoma multiforme
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040630.
FT   VARIANT     723    723       R -> C (in dbSNP:rs35026425).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040631.
FT   VARIANT     729    729       R -> Q (in CLS; dbSNP:rs28935171).
FT                                {ECO:0000269|PubMed:10094187}.
FT                                /FTId=VAR_006197.
FT   CONFLICT     89     89       S -> L (in Ref. 5; AAH96303).
FT                                {ECO:0000305}.
FT   CONFLICT    410    410       Missing (in Ref. 3; BAD92170).
FT                                {ECO:0000305}.
FT   CONFLICT    424    424       V -> L (in Ref. 6; AAC82495).
FT                                {ECO:0000305}.
FT   CONFLICT    480    480       K -> N (in Ref. 6; AAC82495).
FT                                {ECO:0000305}.
FT   CONFLICT    494    494       Missing (in Ref. 6; AAC82495).
FT                                {ECO:0000305}.
FT   HELIX        50     54       {ECO:0000244|PDB:5D9L}.
FT   HELIX        65     67       {ECO:0000244|PDB:4NW6}.
FT   STRAND       68     76       {ECO:0000244|PDB:4NW6}.
FT   STRAND       78     87       {ECO:0000244|PDB:4NW6}.
FT   TURN         91     94       {ECO:0000244|PDB:4NW6}.
FT   STRAND       96    104       {ECO:0000244|PDB:4NW6}.
FT   TURN        105    107       {ECO:0000244|PDB:4NW6}.
FT   HELIX       109    124       {ECO:0000244|PDB:4NW6}.
FT   STRAND      133    139       {ECO:0000244|PDB:4NW6}.
FT   STRAND      142    148       {ECO:0000244|PDB:4NW6}.
FT   STRAND      152    154       {ECO:0000244|PDB:5D9K}.
FT   HELIX       155    162       {ECO:0000244|PDB:4NW6}.
FT   HELIX       167    186       {ECO:0000244|PDB:4NW6}.
FT   STRAND      189    192       {ECO:0000244|PDB:5D9L}.
FT   HELIX       196    198       {ECO:0000244|PDB:4NW6}.
FT   STRAND      199    201       {ECO:0000244|PDB:4NW6}.
FT   STRAND      203    205       {ECO:0000244|PDB:4NUS}.
FT   STRAND      207    209       {ECO:0000244|PDB:4NW6}.
FT   STRAND      214    216       {ECO:0000244|PDB:5D9L}.
FT   HELIX       217    223       {ECO:0000244|PDB:4NUS}.
FT   TURN        224    226       {ECO:0000244|PDB:4NUS}.
FT   HELIX       232    234       {ECO:0000244|PDB:4NW6}.
FT   HELIX       237    240       {ECO:0000244|PDB:4NW6}.
FT   HELIX       249    263       {ECO:0000244|PDB:4NW6}.
FT   HELIX       273    282       {ECO:0000244|PDB:4NW6}.
FT   HELIX       293    302       {ECO:0000244|PDB:4NW6}.
FT   HELIX       307    309       {ECO:0000244|PDB:4NW6}.
FT   TURN        315    318       {ECO:0000244|PDB:4NW6}.
FT   HELIX       319    322       {ECO:0000244|PDB:4NW6}.
FT   HELIX       325    327       {ECO:0000244|PDB:4NW6}.
FT   HELIX       332    336       {ECO:0000244|PDB:4NW6}.
FT   HELIX       351    353       {ECO:0000244|PDB:5D9L}.
FT   STRAND      409    411       {ECO:0000244|PDB:4JG7}.
FT   HELIX       412    414       {ECO:0000244|PDB:4D9U}.
FT   TURN        419    421       {ECO:0000244|PDB:4D9T}.
FT   STRAND      422    430       {ECO:0000244|PDB:4D9T}.
FT   STRAND      432    441       {ECO:0000244|PDB:4D9T}.
FT   TURN        442    445       {ECO:0000244|PDB:4D9T}.
FT   STRAND      446    454       {ECO:0000244|PDB:4D9T}.
FT   TURN        455    457       {ECO:0000244|PDB:4D9T}.
FT   HELIX       461    470       {ECO:0000244|PDB:4D9T}.
FT   STRAND      479    484       {ECO:0000244|PDB:4D9T}.
FT   STRAND      486    494       {ECO:0000244|PDB:4D9T}.
FT   HELIX       501    506       {ECO:0000244|PDB:4D9T}.
FT   HELIX       513    532       {ECO:0000244|PDB:4D9T}.
FT   HELIX       542    544       {ECO:0000244|PDB:4D9T}.
FT   STRAND      545    551       {ECO:0000244|PDB:4D9T}.
FT   HELIX       554    556       {ECO:0000244|PDB:4D9T}.
FT   STRAND      557    559       {ECO:0000244|PDB:4D9T}.
FT   STRAND      571    573       {ECO:0000244|PDB:4JG8}.
FT   HELIX       587    613       {ECO:0000244|PDB:4D9T}.
FT   HELIX       626    635       {ECO:0000244|PDB:4D9T}.
FT   HELIX       643    645       {ECO:0000244|PDB:4D9U}.
FT   STRAND      646    648       {ECO:0000244|PDB:4JG6}.
FT   HELIX       650    659       {ECO:0000244|PDB:4D9T}.
FT   TURN        664    666       {ECO:0000244|PDB:4D9T}.
FT   HELIX       670    673       {ECO:0000244|PDB:4D9T}.
FT   HELIX       677    680       {ECO:0000244|PDB:4D9T}.
FT   HELIX       682    684       {ECO:0000244|PDB:4D9T}.
FT   HELIX       696    710       {ECO:0000244|PDB:4D9T}.
FT   HELIX       711    713       {ECO:0000244|PDB:4JG8}.
SQ   SEQUENCE   740 AA;  83736 MW;  486AE8357CEAB6C8 CRC64;
     MPLAQLADPW QKMAVESPSD SAENGQQIMD EPMGEEEINP QTEEVSIKEI AITHHVKEGH
     EKADPSQFEL LKVLGQGSFG KVFLVKKISG SDARQLYAMK VLKKATLKVR DRVRTKMERD
     ILVEVNHPFI VKLHYAFQTE GKLYLILDFL RGGDLFTRLS KEVMFTEEDV KFYLAELALA
     LDHLHSLGII YRDLKPENIL LDEEGHIKLT DFGLSKESID HEKKAYSFCG TVEYMAPEVV
     NRRGHTQSAD WWSFGVLMFE MLTGTLPFQG KDRKETMTMI LKAKLGMPQF LSPEAQSLLR
     MLFKRNPANR LGAGPDGVEE IKRHSFFSTI DWNKLYRREI HPPFKPATGR PEDTFYFDPE
     FTAKTPKDSP GIPPSANAHQ LFRGFSFVAI TSDDESQAMQ TVGVHSIVQQ LHRNSIQFTD
     GYEVKEDIGV GSYSVCKRCI HKATNMEFAV KIIDKSKRDP TEEIEILLRY GQHPNIITLK
     DVYDDGKYVY VVTELMKGGE LLDKILRQKF FSEREASAVL FTITKTVEYL HAQGVVHRDL
     KPSNILYVDE SGNPESIRIC DFGFAKQLRA ENGLLMTPCY TANFVAPEVL KRQGYDAACD
     IWSLGVLLYT MLTGYTPFAN GPDDTPEEIL ARIGSGKFSL SGGYWNSVSD TAKDLVSKML
     HVDPHQRLTA ALVLRHPWIV HWDQLPQYQL NRQDAPHLVK GAMAATYSAL NRNQSPVLEP
     VGRSTLAQRR GIKKITSTAL
//
